A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
A phase 3 trial of Zolbetuximab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
Overview
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). is a phase 3 interventional study registered as NCT03653507 by Astellas Pharma Global Development, Inc., with 507 participants enrolled, started 2018-11-28 and due to reach its primary completion in 2022-10-25. Interventions recorded: zolbetuximab, oxaliplatin, capecitabine and placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Shares Zolbetuximab, Astellas, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Shares Zolbetuximab, Astellas, Oxaliplatin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Shares Zolbetuximab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Shares Zolbetuximab, Astellas and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Shares Astellas, Gastric & gastro-oesophageal junction cancer and the tag pipeline.